These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 15856427

  • 21. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, Boktour MR, Whimbey EE, Kontoyiannis D, Jacobson K, Kantarjian H, Levett LM, Rolston KV.
    Cancer; 2003 Sep 01; 98(5):1039-47. PubMed ID: 12942573
    [Abstract] [Full Text] [Related]

  • 22. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
    Cooper MR, Durand CR, Beaulac MT, Steinberg M.
    Ann Pharmacother; 2011 Sep 01; 45(9):1094-102. PubMed ID: 21862714
    [Abstract] [Full Text] [Related]

  • 23. Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences.
    Sung L, Feldman BM, Schwamborn G, Paczesny D, Cochrane A, Greenberg ML, Maloney AM, Hendershot EI, Naqvi A, Barrera M, Llewellyn-Thomas HA.
    J Clin Oncol; 2004 Oct 01; 22(19):3922-9. PubMed ID: 15459214
    [Abstract] [Full Text] [Related]

  • 24. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.
    Rolston KV, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS.
    Support Care Cancer; 2010 Jan 01; 18(1):89-94. PubMed ID: 19387695
    [Abstract] [Full Text] [Related]

  • 25. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules.
    Rolston KV, Manzullo EF, Elting LS, Frisbee-Hume SE, McMahon L, Theriault RL, Patel S, Benjamin RS.
    Cancer; 2006 Jun 01; 106(11):2489-94. PubMed ID: 16628654
    [Abstract] [Full Text] [Related]

  • 26. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND, Gan GG, Adeeba K.
    Ann Hematol; 2008 Jul 01; 87(7):563-9. PubMed ID: 18437382
    [Abstract] [Full Text] [Related]

  • 27. Ceftriaxone monotherapy for the treatment of febrile neutropenia in patients with solid tumors: a prospective study of 100 episodes.
    Chamorey E, Magne N, Foa C, Otto J, Largillier R, Viot M, Benard-Thiery I, Thyss A.
    Med Sci Monit; 2004 Nov 01; 10(11):PI119-25. PubMed ID: 15507863
    [Abstract] [Full Text] [Related]

  • 28. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
    Ahmed N, El-Mahallawy HA, Ahmed IA, Nassif S, El-Beshlawy A, El-Haddad A.
    Pediatr Blood Cancer; 2007 Nov 01; 49(6):786-92. PubMed ID: 17366527
    [Abstract] [Full Text] [Related]

  • 29. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.
    Shenep JL, Flynn PM, Baker DK, Hetherington SV, Hudson MM, Hughes WT, Patrick CC, Roberson PK, Sandlund JT, Santana VM, Sixbey JW, Slobod KS.
    Clin Infect Dis; 2001 Jan 01; 32(1):36-43. PubMed ID: 11112678
    [Abstract] [Full Text] [Related]

  • 30. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M, Südhoff T, Fenchel K, Egerer G, Kämpfe D, Ritter J, Franke A, Heil G, Peters G, Jürgens H.
    Wien Med Wochenschr; 1998 Jan 01; 148(21):481-7. PubMed ID: 10048176
    [Abstract] [Full Text] [Related]

  • 31. Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia.
    Petrilli A, Altruda Carlesse F, Alberto Pires Pereira C.
    Pediatr Blood Cancer; 2007 Oct 15; 49(5):682-6. PubMed ID: 17253640
    [Abstract] [Full Text] [Related]

  • 32. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
    Gunderson CC, Farrell R, Dinh BC, Thomas ED, Vesely SK, Lauer JK, Kao L, Chopra S, McMeekin DS, Moore KN.
    Gynecol Oncol; 2013 Sep 15; 130(3):411-5. PubMed ID: 23791827
    [Abstract] [Full Text] [Related]

  • 33. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.
    Mullen CA.
    Pediatr Infect Dis J; 2003 Dec 15; 22(12):1138-42. PubMed ID: 14688588
    [Abstract] [Full Text] [Related]

  • 34. [Febrile neutropenia in the child with cancer. Current concepts about risk assessment and selective management].
    Santolaya ME.
    Rev Med Chil; 2001 Dec 15; 129(12):1449-54. PubMed ID: 12080883
    [Abstract] [Full Text] [Related]

  • 35. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME, Alvarez AM, Avilés CL, Becker A, Cofré J, Cumsille MA, O'Ryan ML, Payá E, Salgado C, Silva P, Tordecilla J, Varas M, Villarroel M, Viviani T, Zubieta M.
    J Clin Oncol; 2004 Sep 15; 22(18):3784-9. PubMed ID: 15365075
    [Abstract] [Full Text] [Related]

  • 36. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC, Bernard JL.
    Anticancer Drugs; 2007 Mar 15; 18(3):277-81. PubMed ID: 17264759
    [Abstract] [Full Text] [Related]

  • 37. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 38. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
    Keating KN, Friedman HS, Perfetto EM.
    Curr Med Res Opin; 2006 Feb 01; 22(2):327-33. PubMed ID: 16466604
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
    Vehreschild JJ, Moritz G, Vehreschild MJ, Arenz D, Mahne M, Bredenfeld H, Chemnitz J, Klein F, Cremer B, Böll B, Kaul I, Wassmer G, Hallek M, Scheid C, Cornely OA.
    Int J Antimicrob Agents; 2012 Feb 01; 39(2):130-4. PubMed ID: 22169408
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.